Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 16, 2026, 6:21 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2833–2856 of 4,346 matching trials from the live ClinicalTrials.gov search.
Conditions
Localized Colon Carcinoma, Stage IIB Colon Cancer AJCC v8, Stage IIC Colon Cancer AJCC v8, Stage III Colon Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Colonoscopy, Computed Tomography, Questionnaire Administration, Toripalimab
Procedure · Other · Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Atlanta, Georgia • Johns Creek, Georgia
Conditions
Ovarian Neoplasms
Interventions
Niraparib, TSR-042, Bevacizumab, Carboplatin, Paclitaxel
Drug · Biological
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
19
States / cities
Birmingham, Alabama • Los Angeles, California • San Francisco, California + 15 more
Conditions
Generalized Myasthenia Gravis
Interventions
Zilucoplan
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
New Haven, Connecticut • Tampa, Florida • Columbia, Missouri + 4 more
Conditions
Myelodysplastic Syndrome, MDS
Interventions
pracinostat, Azacitidine, Decitabine
Drug
Lead sponsor
Helsinn Healthcare SA
Industry
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
21
States / cities
Mobile, Alabama • Duarte, California • Los Angeles, California + 17 more
Completed Not applicable Interventional

Permissive Intrapartum Glucose Control

NCT05553275
Conditions
Gestational Diabetes, Pregestational Diabetes
Interventions
Usual Care, Permissive intrapartum glucose control
Procedure
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Interventions
MK-1092, 4.0 nmol/kg, MK-1092, 8.0 nmol/kg, MK-1092, 16 nmol/kg, MK-1092, 32 nmol/kg, MK-1092, 64 nmol/kg, Glargine 3.0 nmol/kg, Lispro 1.2 nmol/kg, Placebo to glargine, Placebo to MK-1092, Dextrose, Insulin
Drug · Other · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Chula Vista, California
Conditions
Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer, Leukemia Acute Myeloid Leukemia (AML)
Interventions
BAL0891, Tislelizumab, Paclitaxel
Drug · Combination Product
Lead sponsor
SillaJen, Inc.
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
11
States / cities
New Haven, Connecticut • Coral Gables, Florida • Atlanta, Georgia + 6 more
Conditions
Cardiometabolic Conditions, Hypertension (HTN), Dyslipidemia, Pre-diabetes, Type 2 Diabetes Mellitus (T2DM), Overweight (BMI > 25), Weight Loss Trial
Interventions
PILI (Partnership for Improving Lifestyle Intervention) Pasifika Program
Behavioral
Lead sponsor
University of Hawaii
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Fayetteville, Arkansas • Honolulu, Hawaii
Conditions
Smoldering Multiple Myeloma
Interventions
Hiltonol, Citarinostat, Lenalidomide, PVX-410
Drug · Biological
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2027
U.S. locations
6
States / cities
Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more
Terminated Phase 2 Interventional Results available

Nelfinavir in Systemic Lupus Erythematosus

NCT02066311
Conditions
Systemic Lupus Erythematosus
Interventions
Nelfinavir
Drug
Lead sponsor
Northwell Health
Other
Eligibility
18 Years to 65 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
8
States / cities
Los Angeles, California • Chicago, Illinois • Manhasset, New York + 2 more
Conditions
CD40L-HyperIgM Syndrome
Interventions
Base-edited hematopoietic stem and progenitor cells, Alemtuzumab, Sirolimus, Palifermin, Busulfan, Base-edited T lymphocyte cells
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
37 Years to 120 Years · Male only
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
ESRD, Hemodialysis Complication, Blood Pressure
Interventions
TAKE vs. HOLD
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
2
States / cities
Menlo Park, California • San Carlos, California
Completed Phase 2 Interventional Results available

Cardiovascular Effects of COVID-19

NCT04365699
Conditions
COVID-19
Interventions
AT-001
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
New York, New York
Completed Not applicable Interventional

Ambient AI Clinical Trial

NCT07598721
Conditions
Artificial Intelligence (AI), Physician Burnout, Physician Work Environment
Interventions
Use of Ambient AI scribe tool on participant's mobile device
Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Completed Not applicable Interventional Results available

Implementation of Real-time ADE Surveillance and Decision Support

NCT00780572
Conditions
Adverse Drug Events
Interventions
ADE alert assistant
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Terminated Early Phase 1 Interventional Results available

Fermented Wheat Germ Extract in Women With Ovarian Cancer

NCT02411565
Conditions
Ovarian Cancer
Interventions
Fermented Wheat Germ Extract (FWGE), Placebo, Standard of Care: Planned Surgery, Quality of Life (QoL) Surveys: FACT-O
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Treatment Resistant Depression
Interventions
Moderate Intensity Aerobic Exercise, Wait-list
Other
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Hershey, Pennsylvania
Conditions
Type 2 Diabetes Mellitus
Interventions
Sotagliflozin, Placebo
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
14
States / cities
Escondido, California • Greenbrae, California • Walnut Creek, California + 11 more
Conditions
Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm
Interventions
TAS1553
Drug
Lead sponsor
Astex Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
8
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 5 more
Conditions
Diabetic Foot
Interventions
SkinTE, Control
Biological · Other
Lead sponsor
PolarityTE
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
13
States / cities
Fresno, California • Los Angeles, California • Hollywood, Florida + 8 more
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Randomized Controlled Trial Examining Health Care Access Interventions for Taxi Drivers

NCT02508363
Conditions
Healthcare Access for Taxi Drivers
Interventions
questionnaires
Behavioral
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
21 Years to 85 Years · Male only
Enrollment
756 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2027
U.S. locations
1
States / cities
New York, New York
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Sublingual Atropine Bioequivalence by Route of Administration (SABER)

NCT06366087
Conditions
Atropine Bioequivalence
Interventions
Atropine Sulfate Ophthalmic Solution USP, 1%, Atropine Sulfate Injection, USP 8 mg/20 mL (0.4 mg/mL)
Drug
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lenexa, Kansas
Conditions
Ornithine Transcarbamylase Deficiency, Ornithine Transcarbamylase Deficiency Disease, Ornithine Carbamoyltransferase Deficiency (Disorder), Urea Cycle Disorders, Inborn
Interventions
ECUR-506
Genetic
Lead sponsor
iECURE, Inc.
Industry
Eligibility
24 Hours to 7 Months · Male only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
6
States / cities
Los Angeles, California • Aurora, Colorado • Atlanta, Georgia + 3 more
Conditions
Breast Cancer, Breast Neoplasms, Breast Adenocarcinoma, Breast Cancer Stage, Breast Cancer Stage IV, Breast Cancer Invasive, Breast Cancer in Situ
Interventions
Not listed
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
22
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 16 more